Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


03.12.2018

1 Acta Neurol Scand
1 BMJ
1 Clin Ther
2 J Neuroimmunol
3 J Neurol
1 J Neurol Neurosurg Psychiatry
1 J Neurol Sci
2 PLoS One
1 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neurol Scand

  1. PIRTTISALO AL, Soilu-Hanninen M, Sipila JOT
    Multiple sclerosis epidemiology in Finland: regional differences and high incidence.
    Acta Neurol Scand. 2018 Nov 27. doi: 10.1111/ane.13057.
    PubMed     Text format     Abstract available


    BMJ

  2. DE ANGELIS F, John NA, Brownlee WJ
    Disease-modifying therapies for multiple sclerosis.
    BMJ. 2018;363:k4674.
    PubMed     Text format    


    Clin Ther

  3. KRESA-REAHL K, Repovic P, Robertson D, Okwuokenye M, et al
    Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Clin Ther. 2018 Nov 20. pii: S0149-2918(18)30506.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  4. MONTEIRO A, Cruto C, Rosado P, Rosado L, et al
    Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts.
    J Neuroimmunol. 2018;326:49-54.
    PubMed     Text format     Abstract available

  5. ROCHA NP, Colpo GD, Bravo-Alegria J, Lincoln JA, et al
    Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis.
    J Neuroimmunol. 2018;326:45-48.
    PubMed     Text format     Abstract available


    J Neurol

  6. COCOZZA S, Pontillo G, Russo C, Russo CV, et al
    Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?
    J Neurol. 2018 Jul 28. pii: 10.1007/s00415-018-8985.
    PubMed     Text format     Abstract available

  7. KILJAN S, Meijer KA, Steenwijk MD, Pouwels PJW, et al
    Structural network topology relates to tissue properties in multiple sclerosis.
    J Neurol. 2018 Nov 22. pii: 10.1007/s00415-018-9130.
    PubMed     Text format     Abstract available

  8. MEGNA R, Alfano B, Lanzillo R, Costabile T, et al
    Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    J Neurol. 2018 Nov 29. pii: 10.1007/s00415-018-9139.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  9. CHARALAMBOUS T, Tur C, Prados F, Kanber B, et al
    Structural network disruption markers explain disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Nov 22. pii: jnnp-2018-318440.
    PubMed     Text format     Abstract available


    J Neurol Sci

  10. FRITZ NE, Kloos AD, Kegelmeyer DA, Kaur P, et al
    Supplementary motor area connectivity and dual-task walking variability in multiple sclerosis.
    J Neurol Sci. 2018;396:159-164.
    PubMed     Text format     Abstract available


    PLoS One

  11. GIORDANO A, Liethmann K, Kopke S, Poettgen J, et al
    Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey.
    PLoS One. 2018;13:e0208004.
    PubMed     Text format     Abstract available

  12. PAWLITZKI M, Sweeney-Reed CM, Meuth SG, Reinhold D, et al
    CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.
    PLoS One. 2018;13:e0207726.
    PubMed     Text format     Abstract available


    Rev Neurol

  13. PEREZ-ALVAREZ AI, Garcia-Rua A, Suarez-Santos P, Castanon-Apilanez M, et al
    [Appraisal of cerebral atrophy in multiple sclerosis by means of the corpus callosum index].
    Rev Neurol. 2018;67:417-424.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: